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IL-15 has a pivotal role in life and death of natural killer
(NK) and CD8 memory T cells. IL-15 signals through a
heterotrimeric receptor involving the common gamma
chain (gc) shared with IL-2, IL-4, IL-7, IL-9, and IL-21, IL-2/
IL-15 receptor b (IL-15Rb) shared with IL-2 and a private
IL-15Ra subunit. IFN- or CD40 ligand–stimulated den-
dritic cells coordinately express IL-15 and IL-15Ra. Cell
surface IL-15Ra presents IL-15 in trans to cells that
express IL-2/IL-15Rb and gc. IL-15 is being used to treat
patients with metastatic malignancy. However, IL-15 is
an inflammatory cytokine involved in immunological
memory including that to self, thereby playing a role in
autoimmune diseases. These insights provide the
scientific basis for clinical strategies directed toward
diminishing IL-15 action. Dysregulated IL-15 expression
was demonstrated in patients with rheumatoid arthri-
tis, inflammatory bowel disease, psoriasis, celiac dis-
ease, and alopecia areata. The monoclonal antibody
Hu-Mik-b-1 targets the cytokine receptor subunit IL-2/
IL-15Rb (CD122), blocks IL-15 transpresentation, and is
being used in clinical trials in patients with autoim-
mune diseases. In parallel, clinical trials have been
initiated involving the Jak2/3 (Janus kinase-2/3) inhibi-
tor tofacitinib and Jak1/2 inhibitor ruxolitinib to block
IL-15 signaling.
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IL-15 has a pivotal role in the control of the life and death of
natural killer (NK) and memory phenotype CD8 T cells
(Waldmann, 2006). IL-15 signals through a heterotrimeric
receptor that involves the common cytokine receptor g chain
(CD132), which is shared by IL-2, IL-4, IL-7, IL-9, and IL-21,
the IL-2/IL-15 receptor b (IL-15Rb) (CD122) shared with IL-2
and a third unique receptor subunit IL-15Ra. IL-15 uses a
signaling pathway that involves Jak1 (Janus kinase-1), Jak3,
and signal transducer and activator of transcription-5. IL-15
and IL-2 share a number of functions; both cytokines stimulate
the proliferation of many T cell subpopulations, facilitate the
proliferation and synthesis of immunoglobulins by activated B
cells, and are pivotal in the generation and maintenance of
natural killer (NK) cells. However in many adaptive immune
responses, IL-2 and IL-15 have distinct and often competing
functions. IL-2 through its participation in the maintenance of
peripheral CD4þ CD25þ Foxp3 regulatory T cells and its
unique role in activation-induced cell death is involved in the
elimination of self-reactive T cells that have a role in the
pathogenesis of autoimmune diseases. In contrast, IL-15 has
no marked effect on regulatory T cells, is anti-apoptotic in
several systems including IL-2–induced activation-induced cell
death, and by supporting the survival of CD8 memory T cells,
IL-15 is critical in the maintenance of long-lasting, high-affinity
T cell responses to invading pathogens. One factor underlying
the functional differences between IL-2 and IL-15 involves the
distinct modes of action of the two cytokines. In contrast to
IL-2 that is a secreted cytokine, IL-15 is a cell-surface molecule
that signals in the context of an immunological synapse
(Dubois et al., 2002). Following stimulation of monocytes or
dendritic cells with type 1 or type 2 IFNs or the ligation of
CD40 with CD40 ligand or an agonistic anti-CD40
monoclonal antibody, there is the coordinate induction of
IL-15 and IL-15Ra expression. IL-15Ra on the cell surfaces of
monocytes or dendritic cells presents IL-15 in trans to cells
such as CD8þ memory T cells and NK cells that express
IL-2/IL-15Rb and gc but not IL-15Ra (Dubois et al., 2002).
The basic insights concerning the IL-15 cytokine/receptor
system are being translated into novel IL-15-mediated
approaches to the therapy of cancer and as a component of
vaccines. IL-15 has been produced under current good
manufacturing practices (Waldmann et al., 2011). When
IL-15 was administered by continuous intravenous infusion
at 20mg/kg per day for 10 days, it led to a 7-fold increase
in the number of circulating NK cells and a massive 80- to
100-fold increase in the number of circulating effector
memory T cells (Sneller et al., 2011). We have just com-
pleted a Phase I study that involved recombinant IL-15 in
patients with refractory metastatic malignant melanoma and
metastatic renal cell cancer. Furthermore, molecular vaccines
have been generated incorporating IL-15 for HIV, AIDS,
bioterrorism agents, and cancer.
DISORDERS OF IL-15/IL-15R SYSTEM IN AUTOIMMUNE
DISEASES
The scientific studies we have just discussed focus on
augmenting IL-15 action in an effort to increase patient
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immune responses to their tumor and its use as a component
of molecular vaccines. Efforts are also underway with the
opposite goal of defining situations where disorders of IL-15
and its receptor have a pathogenic role in leukemia and
autoimmune diseases, thereby providing the scientific basis for
clinical approaches that are directed toward diminishing IL-15
actions. IL-15 is a proinflammatory cytokine. Further, IL-15
facilitates the fitness and survival of CD8þ memory pheno-
type T cells including self-reactive memory T cells, suggesting
that disordered IL-15 expression may lead to autoimmune
disease. We have developed an assay for serum IL-15/IL-15Ra
and have demonstrated elevations in its level in groups of
patients with T cell large granular lymphocytic leukemia, gD/D
T cell lymphoma, refractory celiac disease, and with type 1
diabetes (Chen et al., 2012). Furthermore, dysregulated IL-15
expression has also been demonstrated in patients with
rheumatoid arthritis, inflammatory bowel disease, psoriasis,
celiac disease, and alopecia areata. Therefore, we have
undertaken a multifaceted research program to develop
novel therapeutic strategies for diseases that are associated
with disordered gc cytokines with a special emphasis on
disorders of the IL-15/IL-15Ra system. One element of this
program includes the development of Hu-Mik-b-1, a
monoclonal antibody directed toward IL-2/IL-15Rb that
blocks IL-15 transpresentation (Waldmann, et al, 2013).
As part of our program, we have obtained Food Drug
Administration permission to use Hu-Mik-b-1 in patients
with refractory celiac disease. Celiac disease is an auto-
immune inflammatory disorder observed predominantly in
humans who carry the HLA-DQ2 or DQ8 alleles. In affected
individuals, intraperitoneal CD8 T lymphocytes show
massive infiltration into the affective intestinal mucosa that
causes extensive destruction of enterocytes and under-
lying tissues primarily by T cell receptor–independent
mechanisms that utilize NKG2D and other coactivating
NK receptors. Emerging evidence has implicated a pivotal
role for IL-15 in this disorder. IL-15 is indispensable for the
generation, maintenance, and homeostasis of IEL. IL-15 also
induces proliferation of CD8 T lymphocytes and their action in
part by the coordinate induction of the NKG2D signaling
pathway. In completing the cycle of this tissue damage,
IL-15 also induces the surface expression of the cognate
ligand of NKG2D, the MHC class I–related antigen-A.
Collectively, these findings implicate a central role for
IL-15 in the pathogenesis of celiac disease and provide a
rationale for selective targeting of IL-15 in patients with the
type II form of refractory celiac disease who have a 40%
incidence of enteropathy-associated T cell lymphoma within
5 years.
In collaboration with S Yokoyama and T Hiroi, we eval-
uated blockade of IL-15 action in IL-15 transgenic mice that
express IL-15 in intestinal cells using an enterocyte-specific
T3b promoter to drive the transgene (Yokoyama et al., 2013).
These mice developed florid inflammation of the duodenal
region, extensive villous atrophy, and massive accumulation
of NK–like CD8þ T cells, a phenomenon that recapitulates
the pathognomic lesions of celiac disease. The administration
of TM-b-1 (the anti-mouse equivalent of Hu-Mik-b-1) directed
toward IL-2/IL-15Rb was associated with the complete reversal
of the macroscopic and microscopic pathologic changes in
the intestine of T3b-h IL-15 Tg mice. In a second trial with this
model, we demonstrated that the administration of the Jak2/3
inhibitor tofacitinib completely reversed the pathological
changes of the transgenic mice. Our results taken together
with the results of studies of patients with refractory celiac
disease provided the rationale for our ongoing collaboration
with Drs Bana Jabri of the University of Chicago and Joseph A
Murray of the Mayo Clinic (Rochester, MN) to initiate a
clinical trial to evaluate Hu-Mik-b-1 in the IL-2/IL-15Rb
directed blockade of IL-15 action.
In an alternative strategy to treat autoimmune and leukemic
diseases associated with disorders of IL-15 action, we are
focusing on the Jak1/Jak3/signal transducer and activator of
transcription-5 signaling pathway utilized by this cytokine.
Our initial studies focused on a human T cell lymphotropic
virus-1–associated adult T cell leukemia. Previously, we
demonstrated that human T cell lymphotropic virus-1 Tax
transactivates two autocrine (IL-2/IL-2R and IL-15/IL-15R) and
one paracrine (IL-9) stimulatory pathway (Chen et al., 2008).
As a consequence of these stimulatory loops, the peripheral
blood mononuclear cells from patients with smoldering and
chronic associated T cell lymphoma spontaneously proli-
ferate ex vivo. This proliferation could be inhibited by the
addition of the Jak2/3 inhibitor tofacitinib or the Jak1/2 inhi-
bitor ruxolitinib (Ju et al., 2011). Taken as a whole, these
preclinical studies suggest the importance of the Jak1/Jak3/
signal transducer and activator of transcription-5 signaling
pathway in the survival of smoldering and chronic asso-
ciated T cell lymphoma malignant lymphocytes. To trans-
late these observations, we have initiated a Phase II trial
with ruxolitinib, a Jak1/Jak2 inhibitor in patients with
smoldering or chronic associated T cell lymphoma. In our
future plans, we wish to use a Jak1–specific inhibitor
in lieu of ruxolitinib so that therapeutic doses can be used
that maintain full inhibition of signal transducer and acti-
vator of transcription-5 phosphorylation throughout the
therapy period without associated dose-limiting thrombo-
cytopenia.
In conclusion, our emerging understanding of the IL-15/
IL-15R systems opens the possibility for the development of
more rational immune interventions that could involve the
evaluation of cytokines, receptor-directed monoclonal anti-
bodies, and small-molecule inhibitors of cytokine signaling for
the treatment of a broad range of leukemias/lymphomas as
well as autoimmune diseases including celiac disease, type 1
diabetes, and alopecia areata.
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